Literature DB >> 15825121

Follow-up of patients with celiac disease: achieving compliance with treatment.

Michelle Maria Pietzak1.   

Abstract

Celiac disease is the only autoimmune condition for which we know the environmental trigger: gluten. Complete removal of gluten from the diet in a patient with celiac disease should result in symptomatic, serologic, and histologic remission. However, compliance with the gluten-free diet, especially in the United States, is extremely challenging. Compliance can be measured both noninvasively, by dietary history and measurement of serum antibodies, and invasively, by using endoscopic and histologic criteria. The advantages and disadvantages of these various modalities are discussed. The highest rates of compliance are reported in patients who are diagnosed as young children, whereas adolescents and those diagnosed via mass serologic screening have the most transgressions. Barriers to compliance include the poor palatability of gluten-free foods, confusing food-labeling practices, and common comorbid psychologic burdens such as anxiety and depression. Because celiac disease is a multisystemic disorder, physicians need to be aware of the potential autoimmune, nutritional, and malignant complications. An algorithm for the follow-up and management of the newly diagnosed celiac disease patient is presented, which includes regular follow-up; measurement of serum antibodies; eliciting a detailed dietary history; and examination for signs and symptoms of nutritional deficiencies, malignancy, and other autoimmune diseases. Ideally, a team approach to the follow-up of the newly diagnosed patient should include regular supervision by an interested physician, medical nutritional counseling by a registered dietician, and access to local and national support groups knowledgeable about this condition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15825121     DOI: 10.1053/j.gastro.2005.02.025

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  42 in total

1.  Pancreatic insufficiency in adult celiac disease: do patients require long-term enzyme supplementation?

Authors:  Kate E Evans; John S Leeds; Stephen Morley; David S Sanders
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

Review 2.  Classification and management of refractory coeliac disease.

Authors:  Alberto Rubio-Tapia; Joseph A Murray
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

3.  Treatment of postmenopausal osteoporosis in a patient with celiac disease.

Authors:  JoAnn V Pinkerton; Alan C Dalkin; Sheila E Crowe; Barbara B Wilson; Edward B Stelow
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

4.  Factors that influence adherence to a gluten-free diet in adults with celiac disease.

Authors:  Daniel A Leffler; Jessica Edwards-George; Melinda Dennis; Detlef Schuppan; Francis Cook; Debra L Franko; Jessica Blom-Hoffman; Ciaran P Kelly
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

5.  Patient perception of treatment burden is high in celiac disease compared with other common conditions.

Authors:  Sveta Shah; Mona Akbari; Rohini Vanga; Ciaran P Kelly; Joshua Hansen; Thimmaiah Theethira; Sohaib Tariq; Melinda Dennis; Daniel A Leffler
Journal:  Am J Gastroenterol       Date:  2014-07-01       Impact factor: 10.864

6.  Oral enzyme therapy for celiac sprue.

Authors:  Michael T Bethune; Chaitan Khosla
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

7.  Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population.

Authors:  Natalia E Castillo; Rohini R Vanga; Thimmaiah G Theethira; Alberto Rubio-Tapia; Joseph A Murray; Javier Villafuerte; Alan Bonder; Rupa Mukherjee; Joshua Hansen; Melinda Dennis; Ciaran P Kelly; Daniel A Leffler
Journal:  Am J Gastroenterol       Date:  2015-07-07       Impact factor: 10.864

8.  Interferon-gamma released by gluten-stimulated celiac disease-specific intestinal T cells enhances the transepithelial flux of gluten peptides.

Authors:  Michael T Bethune; Matthew Siegel; Samuel Howles-Banerji; Chaitan Khosla
Journal:  J Pharmacol Exp Ther       Date:  2009-02-13       Impact factor: 4.030

9.  Noninflammatory gluten peptide analogs as biomarkers for celiac sprue.

Authors:  Michael T Bethune; Mónica Crespo-Bosque; Elin Bergseng; Kaushiki Mazumdar; Lara Doyle; Karol Sestak; Ludvig M Sollid; Chaitan Khosla
Journal:  Chem Biol       Date:  2009-08-28

10.  ACG clinical guidelines: diagnosis and management of celiac disease.

Authors:  Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2013-04-23       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.